Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa
- PMID: 38797173
- DOI: 10.1016/S0140-6736(24)00591-9
Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa
Conflict of interest statement
EM reports consulting fees from Boehringer Ingelheim, Novartis, and Janssen, and speakers' fees from AbbVie, Novartis, and Boehringer Ingelheim, unrelated to the topic of this Comment. OS reports consulting and speakers' fees from AbbVie, Sanofi-Genzyme, and Eli Lilly, and research funding or funding for equipment or drugs from Sanofi-Genzyme, Eli Lilly, LEO Pharma, and Almirall, unrelated to the topic of this Comment.
Comment on
-
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22. Lancet. 2024. PMID: 38795716 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources